Custom Pharma Services renews veterinary licence

December 2017

Custom Pharma are delighted to confirm that our manufacturers licence (MANA) for veterinary medicines was recently approved (MANA 4102) and we are offering contract development and contract manufacturing services for veterinary solid dose forms as well.

Custom Pharma’s laboratory extension

23 May 2017

Custom Pharma have recently complete an expansion on their laboratory at their current facility in Moulsecoomb, Brighton. Extending the analytical lab was done to provide space to accomodate the expanding QC, Development and Stability teams.

Read more

Custom Pharma Services’ £20 million investment in new high containment, development and manufacturing facility in Brighton

19 April 2017

Further to Custom Pharma Services’ earlier announcement on the commencement of the building work on its £20 million investment in a new, high containment development and manufacturing facility in Moulsecoomb, Brighton, we are pleased to provide an update on its progression.

After only 2 months on site, the strip out of the existing building has been completed and the new mezzanine slab constructed.  Initial installation of mechanical and electrical services has started and the main fit out work is imminent, in line with the construction programme.  The new facility will house the contract development, clinical and commercial manufacturing teams in a new, purpose built facility.  This investment is in addition to the previously announced expansion of our analytical laboratories and the ongoing project to introduce serialisation to Custom’s commercial packing lines.

Custom Pharma Services was founded in 1979 as a CMO, focusing exclusively on solid oral dose products.  The decision to expand Custom Pharma’s offer into commercial potent molecules has been led by client enquiries and a detailed assessment of the UKs pharmaceutical manufacturing environment.  The pharmaceutical industry is developing more potent molecules whilst simultaneously the understanding of diseases has led to more stratification in treatment options.  This core understanding and associated creation of personalised medicines has led to the requirement for smaller commercial batches in “state of the art” product containment facilities.  It is important to recognise that Custom will retain its existing capability and capacities for less potent molecules.  The new facility will allow our clients to place both “standard” and potent molecules with us.

Clinical Development

In the clinical arena, Custom is seeing an increase in the potency of molecules and concurrently, a wish from pharmaceutical companies to switch from a simple “drug in capsule” formulation to a more commercially acceptable formulation as early as possible.  The philosophy of “develop once, develop right” has been the mantra of Big Pharma for some time to reduce their time to market and clinical costs.  Within this facility, Custom are investing in both capsule and tableting capabilities for potent clinical development and commercial manufacturing.  Custom has the capability to offer to clients a genuine choice for their solid phase product – from simple capsule formulations that will need refining during the clinical programme to a more complex formulation option, from first intent, that can ensure a smoother clinical and regulatory pathway.

The team at Custom works for clients of all sizes, from virtual pharma to large multinational, who wish to develop their potent new chemical entity or their new generic (or super generic) product.  The ability to deliver clinical and commercial products from the same facility allows our clients to avoid the delays caused by switching between separate clinical CDMO and commercial CMO; and the delays caused by switching between large CMO sites.  The product knowledge, so carefully learnt during the products development lifecycle, is fully retained within Custom by the integrated team.

Regulatory Authorities

The design team who are overseeing the development of this new facility, have been engaged with the regulatory authorities to ensure that the new facility fully meets their expectations.  As a UK facility, the MHRA will inspect the facility once the build has been completed.

Custom Pharma’s new development and manufacturing facility has been designed from the ground-up to be multi-regulatory agency friendly and will allow Custom Pharma Services to manufacture solid oral dose formulations of potent molecules; both for clinical and commercial products.  The new facility will be available for development, clinical and potent commercial manufacturing by the end of 2017.

Business Improvement Techniques and Skills (BITS) Training Programme

21 March 2017

Custom Pharma Services held an awards ceremony on 20th March to celebrate the successful completion of this training programme.  80 operational staff have completed level 2 diplomas in Business Improvement Techniques and 50 of these staff received an upgraded Intermediate Level Apprenticeship qualification.   The awards ceremony took place at the Salvation Army Hall in Conway Street, Hove.  Labour Party MP for Hove Peter Kyle presented the awards to the successful trainees. He praised the Company for their investment in the training and the individuals for the commitment to complete the course.

In 2014 the Company took the decision to invest in continuous improvement training for its operational staff and sourced the BITS programme from Skills Training UK. The programme was made available to all our operational staff. It has taken just over 12 months to complete.  The workforce was split into 14 cross-functional groups (7 on each site).  Learning was via a mixture of classroom learning and project work.  The results of the project work were on display at the awards ceremony, with each group presenting the result of their most valuable project.

CEO of Custom Pharma, Nigel Richardson said “We took a business decision to support a significant number of our staff to gain Business Improvement Skills. Together we have taken over 3,000 hours of work time to study this course and the level of success has been outstanding. The practical skills our employees have gained have already added to productivity, efficiency and enhancing the working environment.

Investing in our people is very important to Custom Pharma and we are pleased to be able to support our staff in developing their skills which in turn helps to improve the performance of our business. Gaining a qualification is always worthwhile and improves the career opportunities for the individual as well as strengthening the skills base within the company, we see this as a win-win for all parties”

Custom Pharma Services Adds New Location to Expand Manufacturing and Development Operations

20 September 2016

We have acquired a new building to expand its high containment manufacturing and development operations. The new facility, the Custom Pharmaceutical Innovation Centre, is co-located on the Fairway Trading Estate in Brighton, adjacent to the company’s existing packaging and warehousing operations. Acquisition of this site will allow us to increase capacity for clinical and product development of highly potent molecules and advance its commercial manufacturing capabilities with high containment capabilities to meet customer demand.

Read more

Custom Pharma Services joins living wage campaign

2 June 2016

Custom Pharma Services have recently subscribed to the Brighton and Hove Living Wage campaign. We are committed to our staff and becoming a living wage company will have a huge impact on our employees. We hope our actions will encourage other local companies to also join the campaign. Our People Director, Tony Rogers, explains more about why we are doing this and the benefits for our staff.

Read more